WHA77 individual statement on climate change and health
On 27 May 2024, IFPMA submitted a statement to the World Health Assembly on Provisional Agenda Item 15.4, Climate change and health.
IFPMA commends the Resolution and the recognition of climate change as an urgent global challenge.
Innovative pharmaceutical companies are setting ambitious, science-aligned targets and investing to develop environmentally sustainable products, manufacturing processes, and supply chains, without compromising safety, quality, and efficacy for best patient outcomes.
Pharmaceutical operations are complex and highly regulated, thus collaboration between industry, governments, regulators, and health systems actors, including suppliers, is required. Likewise, the climate change and health nexus is a multi-faceted area demanding solid collaboration.
The ATACH initiative is an important platform for mobilizing the resources and expertise needed to address this crisis. As a formal member of ATACH, IFPMA looks forward to constructively engaging with its actors by leveraging its sector’s experience, such as science and partnerships.
About IFPMA
IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.
ifpma.org
To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.
